Skip to main content
Sirio Pharma Co., Ltd. logo

Sirio Pharma Co., Ltd. — Investor Relations & Filings

Ticker · 300791 ISIN · CNE100003NB0 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,175 across all filing types
Latest filing 2026-05-27 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300791

About Sirio Pharma Co., Ltd.

https://www.siriopharma.com

Sirio Pharma Co., Ltd. is a global contract development and manufacturing organization (CDMO) specializing in dietary supplements and nutraceuticals. The company provides comprehensive services encompassing product formulation, manufacturing, and packaging. Its portfolio includes diverse delivery formats such as softgels, gummies, tablets, hard capsules, powders, and oral liquids. Sirio Pharma emphasizes innovation in delivery systems, offering specialized solutions like plant-based softgels and advanced probiotic formulations. The organization adheres to rigorous quality management systems and maintains multiple international certifications to meet global regulatory standards. Serving an international clientele, the company supports health and wellness brands through scalable production capacities and integrated supply chain solutions.

Recent filings

Filing Released Lang Actions
关于仙乐转债暂停转股的提示性公告
Capital/Financing Update Classification · 65% confidence The document is a public announcement by Xianle Health Technology Co., Ltd. regarding the suspension and resumption dates of conversion rights for its convertible bonds (bond code: 123113). It does not contain full financial statements or an investor presentation; neither is it a board change, dividend notice, nor proxy materials. This is an update on the company’s capital structure via its convertible bond instrument. Therefore it falls under Capital/Financing Update (CAP).
2026-05-27 Chinese
关于回购注销部分限制性股票暨减少注册资本通知债权人的公告（1）
Share Issue/Capital Change Classification · 78% confidence The document is a formal corporate announcement by 仙乐健康科技股份有限公司 notifying creditors of its planned repurchase and cancellation of restricted shares, leading to a reduction in registered capital. There are no financial statements or performance data—rather, it describes a share repurchase for cancellation and consequent capital change and prescribes creditor claim procedures. This fits the “Share Issue/Capital Change” category (SHA) for announcements regarding capital structure changes such as share cancellations and reductions.
2026-05-22 Chinese
广东信达律师事务所关于仙乐健康科技股份有限公司2025年年度股东会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 85% confidence The document is a legal opinion letter from a law firm concerning the legality of convening, attendance, and voting procedures at the company’s 2025 annual shareholders’ meeting. It details the vote counts and outcomes for each proposal. This matches the definition of an official announcement of shareholder vote results at a general meeting (DVA). It is not merely an announcement of the meeting (RPA) nor a full annual report or interim report. Hence, it is classified as a Declaration of Voting Results & Voting Rights Announcement (DVA).
2026-05-20 Chinese
2025年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 92% confidence The document is a detailed announcement of the 2025 annual general meeting (AGM) resolutions, including meeting attendance, vote counts on each proposal, and formal voting results. It is not the full annual report or financial statements themselves, but the official declaration of shareholder voting outcomes. This fits the definition of “Declaration of Voting Results & Voting Rights Announcements” (Code: DVA).
2026-05-20 Chinese
关于2025年限制性股票激励计划首次授予部分第一个解除限售期解除限售股份上市流通的提示性公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement regarding the unlocking (解除限售) of restricted stock shares under a 2025 restricted stock incentive plan by the company 仙乐健康科技股份有限公司. It includes specifics about the number of shares unlocked, the dates, the conditions met, the approval process by the board and shareholders, and the impact on share capital structure. The document is not a financial report like an annual or interim report, nor is it a call transcript or earnings release. It is a formal announcement about share incentive plan stock unlocking and related corporate governance matters. This type of announcement fits best under the category of Regulatory Filings (RNS), as it is a regulatory disclosure about share incentive plan progress and stock unlocking, not a full report or a voting result announcement. The document length and detail also support it being a regulatory filing rather than a brief announcement or a report publication announcement.
2026-05-08 Chinese
关于2023年限制性股票激励计划首次授予部分第二个解除限售期解除限售股份上市流通的提示性公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement regarding the unlocking (解除限售) of restricted stock under a 2023 restricted stock incentive plan by the company 仙乐健康科技股份有限公司. It includes information about the number of shares unlocked, the dates, the approval process by the board and shareholders, performance conditions, and stock structure changes. The document is not a full financial report, earnings release, or management discussion, but rather a formal announcement about stock incentive plan execution and share unlocking. It is not a proxy solicitation or voting result announcement, nor a remuneration report. The document is regulatory in nature, providing detailed disclosure about share incentive plan progress and stock unlocking, which fits best under Regulatory Filings (RNS) as it does not constitute a full report or financial statement but is a compliance disclosure about stock incentive plan status and share circulation changes.
2026-05-08 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.